Top Trending Tickers On StockTwits For January 29
Here's a look at the top tickers trending on StockTwits.com
Facebook: D-day is today
After the market closes today, Facebook (NASDAQ: FB) will release its fourth quarter results. The consensus estimate for EPS is $0.27 and $2.33 billion in revenue.
Investors have heavily debated Facebook for quite some time, and will continue doing so after today's results. Ad revenue (especially mobile) and trajectory, video ad updates, monetization of Instagram and teen engagement remain several key areas of concern that investors will likely focus on.
Analysts at Goldman Sachs see upside risk to estimates this quarter on both the top and bottom line, especially for mobile.
Analysts at Wedbush said “While we remain constructive on the story, we acknowledge that with the stock up ~15% since the 2Q report (vs. the S&P of ~6%), shares are likely pricing in a strong quarter."
Analysts at Cowen said “Our survey work has consistently pointed to Facebook delivering a high ROI ad product that consistently bests other social peers. Facebook is trading at 11x 2014 EV/Sales, implying the market is supportive of our bullish stance.”
Boeing: Improving profit, light guidance
This morning, Boeing (NYSE: BA) reported its fourth quarter results. The company announced an EPS of $1.88, beating the consensus estimate of $1.57. Revenue of $23.8 billion beat the consensus estimate of $22.74 billion. The company's net profit increased 26 percent to $1.23 billion in the quarter, up from $978 million a year ago.
Investors showed some concerns over the company's 2014 guidance. The company is guided its core EPS in a range of $7 to $7.20, below the consensus of $7.57. Revenue is guided in a range of $87.5 billion to $90.5 billion, below the consensus of $92.7 billion.
Dow Chemical: Earnings beat, company announces dividend and buyback
Dan Loeb's stake in Dow Chemical (NYSE: DOW) is a lot more valuable this morning after the company reported its fourth quarter results. The company announced an EPS of $0.65, beating the consensus estimate of $0.43. Revenue of $14.4 billion beat the consensus estimate of $14.13 billion.
The company announced it will be increased its quarterly dividend by 15.6 percent to $0.37 a share and tripled the size of its 2014 buyback authorization to $4.5 billion.
Management's outlook appears to focus on the activist investor Loeb who assumed a $1.3 billion stake in the company on January 21.
"[The results are] clear evidence of our ability to manage all aspects of our integrated business to generate strong financial performance in an uncertain world ... Our actions to improve return on capital, grow profitability and generate cash are accelerating as we go deeper into attractive end-use markets, exit complex but non-strategic assets and value chains, and maintain a strong focus on productivity metrics and cost controls."
JetBlue: Profit soars
This morning, JetBlue (NASDAQ: JBLU) released its fourth quarter results. The company announced an EPS of $0.14, beating the consensus estimate of $0.13. Revenue of $13.7 billion beat the consensus estimate of $1.35 billion.
The company said that higher ticket prices helped bolster revenue, but the “strong” revenue trend will ease in the coming quarter. The company was forced to cancel 1,800 flight cancellations due to harsh cold weather would hurt its first quarter results.
“The severe weather reduced JetBlue's total revenue by an estimated $45 million and reduced operating income for the first quarter by approximately $30 million,” the company said in a press release.
Biogen: Earnings beat, EPS guidance disappoint
This morning, Biogen (NASDAQ: BIIB) released its fourth quarter results. The company announced an EPS of $2.34, beating the consensus estimate of $2.27. Revenue of $2 billion beat the consensus estimate of $1.93 billion.
Sales of its multiple-sclerosis treatment, Tecfidera, totaled $398 million. According to the company's earnings press release “TECFIDERA revenues represented incremental inventory in the channel.”
The company issued guidance and sees its 2014 EPS of $11 to $11.20, below the consensus estimate of $11.65. Revenue of $8.46 billion to $8.67 is guided above the $8.36 billion consensus.
The company also said its press release that throughout 2014 it expects six data read-outs for several compounds currently in early-to-mid stage clinical trials.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.